Celsion Corp. (CLSN) presented the final data from its Phase Ib clinical trial, combining GEN-1 with the standard of care, at the American Association of Cancer Research Special Conference.
from RTT - Before the Bell http://ift.tt/2xgsbnL
via IFTTT
No comments:
Post a Comment